General information
Formycon AG
Fraunhoferstraße 15
82152 Martinsried/Planegg, Bavaria
Germany
Contact person: Stefan Glombitza, Chief Executive Officer
Company main phone: +49 (89) 864667100
Company main fax: +49 (89) 864667110
Website: https://www.formycon.com
Year founded: | 1999
|
Source of foundation: | Independent foundation |
No. of employees: |
Worldwide: 224 |
Corporate description / mission:
Formycon is a developer of biopharmaceutical medicines, especially biosimilars. The company is focused on the treatments in ophthalmology, immunology and on other key chronic diseases.
State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 2012
Categorization
Sector: |
- Pharma (fully integrated)
|
Subsector: |
- Anti-infectives
- Biosimilars
- Immunotherapy
|
Primary therapeutic areas: |
- Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
- Diseases of the eye / ophthalmology
- Infectious and parasitic diseases / infectiology / parasitology
- Neoplasms / cancer / oncology
- Skin and subcutaneous tissue / dermatology
- Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
|
Customer segments: |
- Large biotech & big pharma
- Small biotech
|
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical: | 2 | |
Phase III: | 2 | |
On the market: | 1 | |
Description of products:
FYB201
FYB202
FYB203
FYB207 etc.
Financing details
Fiscal year (end of) 2022
Revenues: | EUR 42.50M | |
R&D expenses: | EUR 16.91M | |
Net earnings: | EUR 35.99M | |
No. of shares: | 16'038'800 | |
Market cap. / valuation: | EUR 877.24M | |